{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:51:47Z","timestamp":1782305507753,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.annder.2024.103329","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T19:55:18Z","timestamp":1739303718000},"page":"103329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Methotrexate in monotherapy or combined with oral steroids for bullous pemphigoid in a real-life setting: A retrospective monocentric cohort"],"prefix":"10.1016","volume":"152","author":[{"given":"M.","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Du Thanh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lesage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bessis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-C.","family":"Picot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Dereure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2024.103329_b0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12016-017-8633-4","article-title":"Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management","volume":"54","author":"Amber","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.annder.2024.103329_b0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12026-017-8975-2","article-title":"Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"key":"10.1016\/j.annder.2024.103329_b0015","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamadermatol.2020.5598","article-title":"Mixed individual-aggregate data on all-cause mortality in bullous pemphigoid: a meta-analysis","volume":"157","author":"Tedbirt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2024.103329_b0030","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study","volume":"129","author":"Joly","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0035","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103329_b0040","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/bjd.14285","article-title":"Assessment of adherence to topical corticosteroids in bullous pemphigoid patients","volume":"174","author":"Sobocinski","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0045","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0190-9622(94)70227-6","article-title":"Low-dose methotrexate treatment in elderly patients with bullous pemphigoid","volume":"31","author":"Paul","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0050","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/archderm.139.11.1506-b","article-title":"Methotrexate for bullous pemphigoid: preliminary study","volume":"139","author":"Bara","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0055","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2133.2011.10531.x","article-title":"Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study","volume":"165","author":"Du-Thanh","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0060","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/archderm.138.9.1255","article-title":"Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases","volume":"138","author":"Dereure","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0065","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/archderm.144.5.612","article-title":"A retrospective analysis of patients with bullous pemphigoid treated with methotrexate","volume":"144","author":"Kjellman","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0070","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.jaad.2020.01.084","article-title":"Low-dose methotrexate use and safety for older patients with bullous pemphigoid and impaired renal function: a cohort study","volume":"82","author":"Fisch","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1684\/ejd.2019.3501","article-title":"Methotrexate is safe and efficient as long-term treatment for bullous pemphigoid","volume":"29","author":"Delaumenie","year":"2019","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0080","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0190-9622(99)70156-8","article-title":"Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid","volume":"40","author":"Heilborn","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0085","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.annder.2017.09.087","article-title":"Corticoth\u00e9rapie locale br\u00e8ve + m\u00e9thotrexate vs corticoth\u00e9rapie locale seule prolong\u00e9e dans la pemphigo\u00efde bulleuse: essai national multicentrique","volume":"144","author":"Dereure","year":"2017","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2024.103329_b0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000075040","article-title":"Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera","volume":"208","author":"Joly","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2024.103329_b0095","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definition and outcome measures for Bullous Pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0100","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. US Department of Health and Human Services; 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"10.1016\/j.annder.2024.103329_b0105","unstructured":"https:\/\/www.has-sante.fr\/jcms\/c_2636201\/fr\/pemphigoide-bulleuse."},{"key":"10.1016\/j.annder.2024.103329_b0110","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/1346-8138.15111","article-title":"Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)","volume":"46","author":"Ujiie","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1590\/abd1806-4841.2019940207","article-title":"Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology","volume":"94","author":"Santi","year":"2019","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0120","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/07853890.2018.1443346","article-title":"Relapse of bullous pemphigoid: an update on this stubborn clinical problem","volume":"50","author":"Wang","year":"2018","journal-title":"Ann Med"},{"key":"10.1016\/j.annder.2024.103329_b0125","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.3390\/jcm11113193","article-title":"Methylprednisolone plus low-dose methotrexate for bullous pemphigoid - a single center retrospective analysis","volume":"11","author":"Gravani","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.annder.2024.103329_b0130","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002512-200825080-00001","article-title":"Role of methotrexate in the treatment of bullous pemphigoid in the elderly","volume":"25","author":"Patton","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.annder.2024.103329_b0135","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2133.2009.09246.x","article-title":"Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid","volume":"161","author":"G\u00fcrcan","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2024.103329_b0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.45132","article-title":"Low-dose methotrexate and serious adverse events among older adults with chronic kidney disease","volume":"6","author":"Muanda","year":"2023","journal-title":"JAMA Netw Open"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963824000851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T21:31:36Z","timestamp":1741901496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963824000851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0151963824000851"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2024.103329","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methotrexate in monotherapy or combined with oral steroids for bullous pemphigoid in a real-life setting: A retrospective monocentric cohort","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2024.103329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103329"}}